Namenda Related Published Studies
Well-designed clinical trials related to Namenda (Memantine)
Memantine in patients with moderate to severe Alzheimer's disease: meta-analyses
using realistic definitions of response. [2014]
Genotype variant associated with add-on memantine in bipolar II disorder. [2014]
Vitamin E and memantine in Alzheimer's disease: clinical trial methods and
baseline data. [2014]
Memantine effects on verbal memory in fragile X-associated tremor/ataxia syndrome
(FXTAS): a double-blind brain potential study. [2014]
Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for
the treatment of Alzheimer's disease: a systematic review and meta-analysis. [2014]
Add-on memantine to valproate treatment increased HDL-C in bipolar II disorder. [2013]
Memantine add-on to risperidone for treatment of negative symptoms in patients
with stable schizophrenia: randomized, double-blind, placebo-controlled study. [2013]
Memantine in patients with frontotemporal lobar degeneration: a multicentre,
randomised, double-blind, placebo-controlled trial. [2013]
Memantine as adjunctive treatment to risperidone in children with autistic
disorder: a randomized, double-blind, placebo-controlled trial. [2013]
The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: Findings from a 12-month naturalistic trial. [2012.01]
Donepezil and memantine for moderate-to-severe Alzheimer's disease. [2012]
Memantine and functional communication in Alzheimer's disease: results of a
12-week, international, randomized clinical trial. [2012]
A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. [2011.12.01]
Alzheimer's disease - input of vitamin D with mEmantine assay (AD-IDEA trial): study protocol for a randomized controlled trial. [2011.10.20]
Memantine in systemic lupus erythematosus: a randomized, double-blind placebo-controlled trial. [2011.10]
Memantine and Functional Communication in Alzheimer's Disease: Results of a 12-Week, International, Randomized Clinical Trial. [2011.09.28]
Lack of evidence for the efficacy of memantine in mild Alzheimer disease. [2011.08]
Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study. [2011.07]
Effect of memantine on resting state default mode network activity in Alzheimer's disease. [2011.03.01]
Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial. [2011.03]
[Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson's disease]. [2011.02.01]
Memantine prevents hypoglycemia-induced decrements of the cerebral energy status in healthy subjects. [2011.02]
Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment. [2011.02]
A double-blind, double-dummy, randomized controlled study of memantine versus buprenorphine in naloxone-precipitated acute withdrawal in heroin addicts. [2011.01]
Memantine in behavioral variant frontotemporal dementia: negative results. [2011]
Alzheimer's disease--input of vitamin D with mEmantine assay (AD-IDEA trial):
study protocol for a randomized controlled trial. [2011]
Memantine for non-motor features of Parkinson's disease: a double-blind placebo
controlled exploratory pilot trial. [2011]
Memantine discontinuation and the health status of nursing home residents with Alzheimer's disease. [2010.11]
A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. [2010.10]
The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. [2010.10]
Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. [2010.10]
A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period. [2010.09.01]
Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment. [2010.07.21]
Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. [2010.06]
Crossover trial of gabapentin and memantine as treatment for acquired nystagmus. [2010.05]
Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy. [2010.03]
A randomized trial of memantine as treatment for spasticity in multiple sclerosis. [2010.02]
A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis. [2010.02]
Memantine for AIDS dementia complex: open-label report of ACTG 301. [2010.01]
A randomized, placebo-controlled trial of memantine for functional disability in
amyotrophic lateral sclerosis. [2010]
Memantine for cognitive impairment in multiple sclerosis: a randomized
placebo-controlled trial. [2010]
Memantine for AIDS dementia complex: open-label report of ACTG 301. [2010]
Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. [2009.10]
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT. [2009.07.24]
Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation. [2009.07]
Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. [2009.07]
Efficacy and safety of memantine in Lewy body dementia. [2009.07]
Randomized controlled trial of memantine in dementia associated with Parkinson's disease. [2009.06.15]
The effects of memantine on prepulse inhibition. [2009.06]
Memantine induces reversible neurologic impairment in patients with MS. [2009.05.12]
Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia. [2009.05]
A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. [2009.04]
Memantine for prophylaxis of chronic tension-type headache--a double-blind, randomized, crossover clinical trial. [2009.03]
Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine. [2008.12]
Randomized, placebo-controlled, crossover trial of memantine for cognitive changes with corticosteroid therapy. [2008.10.15]
A 6-month, open-label study of memantine in patients with frontotemporal dementia. [2008.07]
[Effect of memantine treatment on patients with moderate-to-severe Alzheimer's disease treated with donepezil] [2008.07]
Randomized, Placebo-Controlled, Crossover Trial of Memantine for Cognitive Changes with Corticosteroid Therapy. [2008.06.24]
Tinnitus treatment with memantine. [2008.04]
Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. [2008.03]
Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. [2008.03]
Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. [2008.02]
A 6-month, open-label study of memantine in patients with frontotemporal dementia. [2008.01.22]
The use of truncated area under the curves in the bioequivalence evaluation of long half-life drugs. Studies with donepezil and memantine. [2008]
Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. [2007.09.12]
Pilot trial of memantine in the treatment of posttraumatic stress disorder. [2007.06]
A pilot double-blind treatment trial of memantine for alcohol dependence. [2007.05]
A double-blind, placebo-controlled trial of memantine in age-associated memory impairment (memantine in AAMI). [2007.05]
Continuous brachial plexus blockade in combination with the NMDA receptor antagonist memantine prevents phantom pain in acute traumatic upper limb amputees. [2007.04]
A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. [2007.04]
Memantine fails to facilitate partial cigarette deprivation in smokers--no role of Memantine in the treatment of nicotine dependency? [2007.03]
Congenital nystagmus: Randomized, controlled, double-masked trial of memantine/gabapentin. [2007.02.05]
Congenital nystagmus: randomized, controlled, double-masked trial of memantine/gabapentin. [2007.02]
Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial. [2007.01]
Clock drawing and frontal lobe behavioral effects of memantine in Alzheimer's disease: a rater-blinded study. [2006.12]
Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. [2006.10]
Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. [2006.10]
Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. [2006.08]
Memantine Treatment in Mild to Moderate Alzheimer Disease: A 24-Week Randomized, Controlled Trial. [2006.07.21]
Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. [2006.07.11]
Cost-effectiveness of memantine in community-based Alzheimer's disease patients: An adaptation in Spain. [2006.06]
Continuous brachial plexus blockade in combination with the NMDA receptor antagonist memantine prevents phantom pain in acute traumatic upper limb amputees. [2006.05.19]
A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. [2006.05]
Memantine for dementia. [2006.04.19]
[Clinical efficacy and safety of akatinol memantine in treatment of mild to moderate Alzheimer disease: a donepezil-controlled, randomized trial] [2006.04]
A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. [2006.01]
Adding Memantine to Rivastigmine Therapy in Patients With Mild-to-Moderate Alzheimer's Disease: Results of a 12-Week, Open-Label Pilot Study. [2006]
Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study. [2005.10]
An evaluation of the reinforcing effects of memantine in cocaine-dependent humans. [2005.08.01]
Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden. [2005.06]
Memantine hydrochloride: pharmacological and clinical profile. [2004.08]
Memantine enhances autonomy in moderate to severe Alzheimer's disease. [2004.05]
A placebo-controlled randomized crossover trial of the N-methyl-D-aspartic acid receptor antagonist, memantine, in patients with chronic phantom limb pain. [2004.02]
Acute effects of memantine in combination with alcohol in moderate drinkers. [2004.02]
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. [2004.01.21]
Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain--results of a randomized double-blinded, placebo-controlled trial. [2003.06]
Memantine in moderate-to-severe Alzheimer's disease. [2003.04.03]
Memantine in vascular dementia. [2003]
Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. [2003]
Memantine for dementia. [2003]
A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). [2002.11]
|